PacBio (PACB) Price-to-Projected Revenue Ratio
The forward P/S dynamics for Pacific Biosciences (PACB) reflect a metric value of 3.80, which warrants caution in valuation. The business is currently undergoing a phase of minimum scientific capital expenditure while awaiting sales growth for new instruments. Production relies on sterile facilities and R&D centers in the US. A unique long-read DNA sequencing ecosystem makes the equipment indispensable in medicine.
Analytical breakdowns for Pacific Biosciences
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt and liquidity data:
Total Debt to Capital Pacific Biosciences|PACB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Pacific Biosciences|PACB - Company Cumulative Debt|Debt to Book Capitalization Ratio PacBio Corp|PACB - Company Long-Term Indebtedness|Company Short-Term Debts PacBio|Quick Ratio pacb.com
- business earnings and investment ratios data:
PACB - Company Net Income|Expected Profit Pacific Biosciences|PACB - Business Payback Period|Future Price to Earnings Pacific Biosciences of California|PACB - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple PacBio Corp|PACB - Operating profit EBITDA|Net earnings per share (EPS TTM) PacBio|PACB - Net earnings per share for the last 12 months|Quarterly EPS earnings growth pacb.com|PACB - Earnings per share growth in current year|Earnings growth forecast for next year Pacific Biosciences
- sales volume and revenue indicators:
Initial company analysis:PACB (PacBio)
For Pacific Biosciences (PACB), whose scaling model relies on high-margin consumables for sequencing systems, the forward P/S dynamics serve as an indicator of market expectations regarding revenue growth rates. This metric compares current market capitalization with projected sales volume, allowing investors to determine the asset's degree of overvaluation or identify a shift in market sentiment by comparing it with historical averages.
Competitor analysis for Pacific Biosciences
Forward P/S Multiple TEM (Tempus AI, Inc.)|Market Cap to Expected Sales Ratio Qiagen NV (QGEN)|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Repligen Inc.|Avidity Biosciences (RNA) - Price-to-Projected Revenue Ratio|CRSP - Market Cap to Expected Sales Ratio|WGS (GeneDx) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Ultragenyx Pharmaceutical Inc. (RARE)|Forward P/S Multiple BEAM|Market Cap to Expected Sales Ratio Sarepta Corp|Forward P/S Multiple TWST (Twist Bioscience)|10xgenomics.com (TXG) - Market Cap to Future Revenue Ratio|NTLA - Price-to-Projected Revenue Ratio|STOK (Stoke Therapeutics Inc) - Market Cap to Projected Revenue|BLFS: Forward P/S Multiple|Forward Price-to-Revenue Multiple Wave Pharma|MAZE (Maze Therapeutics Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio sionnatx.com SION|Price-to-Projected Revenue Ratio Prime Medicine (PRME)|Market Cap to Expected Sales Ratio Taysha Gene Therapies Inc|Price-to-Projected Revenue Ratio uniQure Corp QURE|MGTX (MeiraGTx Corp) - Future Price to Revenue|REGENXBIO Inc. - Forward P/S Multiple|SLDB - Forward P/S Multiple|OCGN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Benitec Biopharma Inc|DSGN (Design Pharma) - Forward P/S Multiple|Price-to-Projected Revenue Ratio RCKT|Forward P/S Multiple FDMT|lexeotx.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Korro Bio KRRO|EDIT: Market Cap to Projected Revenue|Silence Therapeutics Inc. - Forward P/S Multiple|PRQR - Forward P/S Multiple|codexis.com (CDXS) - Price-to-Projected Revenue Ratio|Future Price to Revenue SGMO (sangamo.com)|NAUT (Nautilus Biotechnology, Inc.) - Forward P/S Multiple|Forward P/S Multiple Metagenomi Inc.|Forward P/S Multiple DTIL|Forward Price-to-Revenue Multiple generationbio.com GBIO|Forward P/S Multiple BOLD (Boundless Bio, Inc.)|Market Cap to Expected Sales Ratio Exicure Inc. (XCUR)|Celsion Corporation - Forward P/S Multiple|Future Price to Revenue PHIO|MBIO: Forward P/S Multiple|RNAZ - Market Cap to Expected Sales Ratio|BNGO (Bionano Genomics Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple adnas.com (APDN)|Forward Price-to-Revenue Multiple BLUE (bluebird bio)|IPA (immunoprecise.com) - Forward Price to Sales|Forward P/S Multiple OMGA (Omega)|Singular Genomics Corp - Price-to-Projected Revenue Ratio|Regulus Therapeutics - Forward P/S Multiple|Market Cap to Expected Sales Ratio syros.com SYRS|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio TRACON Pharmaceuticals Inc. (TCON)|Price-to-Projected Revenue Ratio Unity Bio
